Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial | Trials | Full Text
Figure 1 from Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction. | Semantic Scholar
JCM | Free Full-Text | Pharmacodynamics and Outcomes of a De-Escalation Strategy with Half-Dose Prasugrel or Ticagrelor in East Asians Patients with Acute Coronary Syndrome: Results from HOPE-TAILOR Trial | HTML
Dr. Sheila Sahni on Twitter: "Algorithm for switching between oral P2Y12 inhibitors in the acute and chronic setting. (For the Figure: LD = loading dose; MD = maintenance dose) Source: 2017 ESC
Pharmacodynamic profiles of switching from ticagrelor to clopidogrel... | Download Scientific Diagram
Dosing & Administration | BRILINTA® (ticagrelor) tablets | For HCPs
Effect of preoperative loading dose ticagrelor and clopidogrel on no-r | DDDT
Trial schema for the IMPRESSION study. Legend: IV: intravenous; PCI:... | Download Scientific Diagram
Guided P2Y12 inhibitor therapy after percutaneous coronary intervention - The Lancet
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention - ScienceDirect
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial - The Lancet
Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial | Scientific Reports
Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI - ScienceDirect
2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy - Canadian Journal of Cardiology
Brilinta (Ticagrelor Tablets for Oral Administration): Uses, Dosage, Side Effects, Interactions, Warning
Antiplatelet therapy in coronary artery disease
Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health - Journal of Cardiology
Comparison of the Antiplatelet Effects of Once and Twice Daily Low-Dose Ticagrelor and Clopidogrel After Percutaneous Coronary Intervention - American Journal of Cardiology
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada - CJC Open
Study of Two Dose Regimens of Ticagrelor Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease | Semantic Scholar
Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study | BMC Cardiovascular Disorders
